Mechanistic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01 Clinical Trial Not Allowed) | RFA NS 19 039

Frequently Asked Questions (FAQs)

What is the funding opportunity?

This NIH opportunity is titled "Mechanistic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID) (R01 Clinical Trial Not Allowed)" and has Funding Opportunity Number RFA-NS-19-039. It uses the R01 grant mechanism.

What is the main purpose of this FOA?

The FOA supports fundamental, mechanistic research to explain why diffuse white matter disease develops, how it progresses over time, and how it disrupts brain function in ways that contribute to cognitive impairment and dementia in aging. The intent is to move beyond descriptive imaging findings and toward a clearer biological and physiological understanding that can inform future strategies to reduce the public health burden of vascular-related cognitive decline.

Is this opportunity focused on clinical trials?

No. This is an "R01 Clinical Trial Not Allowed" FOA, meaning the funded research must stay within the non-clinical-trial boundary described by NIH for this announcement.

What disease area does the FOA address?

The FOA addresses diffuse white matter disease in the context of vascular contributions to cognitive impairment and dementia (VCID), particularly as it relates to aging and cerebrovascular disease.

What does the FOA mean by "diffuse white matter disease"?

The FOA emphasizes that diffuse white matter disease is not a single uniform lesion. It can reflect a collection of related pathologies, including demyelination, axonal or fiber loss, and damage driven by multifocal small infarcts and chronic local ischemia.

How is diffuse white matter disease commonly detected or characterized?

Clinically, it is commonly detected as white matter hyperintensities on MRI or as signal loss on CT. It can also be confirmed and characterized through histological examination in human brain tissue and in animal models.

Where in the brain is this white matter disease typically found?

The FOA notes that abnormalities frequently appear around the ventricles (periventricular white matter), but can also be present in subcortical white matter. This supports the idea that different white matter regions may have distinct vulnerabilities and disease trajectories.

What vascular or related brain pathologies are described as being associated with diffuse white matter disease?

The FOA links diffuse white matter disease with cerebrovascular disease and notes that it is often seen alongside arteriosclerosis in small deep penetrating arteries. It may also co-occur with multiple infarcts in areas such as the basal ganglia, brainstem, or cerebellum.

Why is NIH emphasizing mechanisms rather than imaging descriptions?

The FOA highlights that, despite frequent observation and strong associations with cognitive outcomes, major knowledge gaps remain. NIH is seeking studies that clarify cellular and molecular causes, explain why certain regions are more vulnerable, describe how the disease evolves over time, and uncover functional consequences for axons and neural circuits.

What are the key knowledge gaps this FOA wants to address?

Based on the FOA description, key gaps include: (1) unresolved cellular and molecular causes; (2) reasons for regional vulnerability differences; (3) how diffuse white matter disease evolves and progresses; and (4) the physiological consequences for local axons and broader neural circuits, which are described as almost completely unknown.

What kinds of research approaches are considered responsive?

Responsive projects are expected to investigate mechanisms across multiple levels of analysis, including molecular, cellular, tissue, and circuit-level biology. The FOA describes approaches such as pathology-based studies, imaging-linked biology, and translationally relevant animal or other model systems, as long as the work remains within the "clinical trial not allowed" scope.

Is the FOA limited to one level of biology (for example, only molecular work or only imaging)?

No. The FOA explicitly emphasizes mechanistic investigation across multiple levels (molecular, cellular, tissue, and circuit). It also encourages moving beyond purely descriptive imaging findings by linking observations to biological mechanisms and functional impacts.

Does the FOA require a focus on how white matter injury affects brain function?

The FOA strongly emphasizes function, stating that physiological consequences for local axons and broader neural circuits are largely unknown and need investigation. The goal is to understand how vascular-related white matter injury could alter communication within the brain in ways that plausibly produce cognitive symptoms.

Is the goal to develop or test treatments?

The funded work is positioned as foundational: it aims to generate mechanistic knowledge that can eventually guide prevention or intervention strategies. However, the FOA is not for testing treatments in human trial formats under this announcement.

What populations or demographics are implicated by the FOA description?

The FOA frames the condition as a very common set of brain changes seen in older adults and notes that white matter injury is strongly associated with VCID in both men and women.

What grant mechanism is used?

This opportunity uses the NIH R01 mechanism.

What is the funding activity category?

The announcement is described as a discretionary NIH grant within the health funding activity category.

Which CFDA numbers are associated with this opportunity?

The opportunity is associated with CFDA numbers 93.853 and 93.866.

What was the closing date listed for this opportunity?

The original closing date listed was 2019-08-14.

Is this FOA connected to earlier NIH announcements?

Yes. It is described as a reissue of earlier announcements (RFA-NS-16-021 and PAR-18-413), indicating continued NIH interest in building a coherent research base around diffuse white matter mechanisms in VCID.

Who is eligible to apply?

Eligibility is broad and includes many types of U.S. governmental units (state, county, city/township, special districts), independent school districts, public and private institutions of higher education, and a range of nonprofit and for-profit organizations (including small businesses).

Are tribal governments and tribal organizations eligible?

Yes. The FOA explicitly encourages participation from tribal governments and organizations, including those other than federally recognized as described in the "other eligible applicants" listing.

Are U.S. territories or possessions included?

Yes. The FOA explicitly encourages participation from U.S. territories or possessions.

Are foreign (non-U.S.) entities eligible?

Yes. The FOA explicitly includes non-U.S. (foreign) entities and regional organizations among the encouraged participants.

Does NIH encourage applications from specific institution types?

Yes. The FOA explicitly encourages participation from a wide variety of institutions and communities, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, and faith-based and community-based organizations.

What is the long-term public health motivation behind this program?

The long-term intent is to generate mechanistic understanding that can ultimately help guide strategies to reduce the public health burden of vascular-related cognitive decline, by clarifying the etiology, progression, and functional impact of vascular-related diffuse white matter injury.